Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| The Part 1 results were clearly better than we had expected and our positive view on BX004 was further reinforced based on supportive feedback from this year's EC/FC meeting |
| We are delighted to update that patients screening for Part 2 of our Phase Ib/IIa study has been completed with patient enrollment expected to exceed original estimates reflecting solid execution by our clinical operations team, along with a growing awareness among physicians and patients within the cystic fibrosis community and the potential of this innovative program |
| In summary, we are very pleased with the continued progress in the BX004 program |
| I think there's been very good execution from the team |
| The feedback we're receiving from physicians, patients, and other stakeholders within the CF community has been highly positive and is constructive, reinforcing our view in the therapeutic potential of BX004 to treat life-threatening infection CF patients are facing |
| I think that helps us in, getting more data and thinking about the next studies, right? So, I think that would be fantastic and, again, excited |
| In February 2023, we announced positive results from Part 1 of the trial, which came in better than expected based on the treatment arm displaying notable reductions in PSA bacterial burden |
| I'm also pleased to announce that BX004 has just received Fast Track designation from the FDA, which provides further recognition that the BX004 program is addressing one of the most serious and challenging unmet medical needs facing the CF community |
| Based on our promising results thus far, we believe BX004 is emerging as a potential viable therapeutic candidate to address the significant unmet medical need in CF |
| I'm pleased to report that we continue to make significant progress in our BX004 program |
| So, as you mentioned, basically enrollment and patient accrual went a lot better than we expected |
| The FDA defines addressing a significant unmet medical need as providing a therapy when non-exists or providing a therapy which may be potentially better than available therapies |
| This is going very, very well in Part 2 |
| So I do think that if part 2 looks as good as part 1, right, then there's a second independent replication, the randomly controlled study with phage with placebo that is showing an effect, right? I think that would give us and hopefully, others the confidence that we've got a good handle on this new modality, and I think that could open up multiple panels for discussions, right? Because there's more indications, there's more we can do -- and with phage, you can move relatively quickly to the clinic with additional programs |
| I think what we've seen is some of the sort of excitement among the sites -- and what we're seeing is more patients that have been referred by the sensors and more patients, kind of, passing through the screening than we originally anticipated and the decision that we took that the more the area |
| During the first half of 2023, we made significant progress in advancing our BX004 program |
| We, therefore, believe that BX004 is one of the few and most promising early clinical candidates for treating these infections in CF patients |
| There's excitement from the Part 1 data |
| It definitely helps to have more patients ahead of the pivotal start |
| So, we're definitely, it's a tough and another good question, right? I think we've got the fast track designation |
| All excellent questions |
| I can say unequivocally that physicians were excited with the notable reduction in bacterial burden displayed in Part 1 of our study that we came away from the ECFC meeting with the impression in the chronic PSA pulmonary infections continue to pose a challenging unmet need for CF patients today |
| This momentum is already carried through into the second half of 2023, with the FDA granting BX004 Fast Track designation and the completion of patient screening in Part 2 of a Phase 1b/2a trial |
| Good morning, guys |
| Good afternoon |
| Additionally, we received higher proceeds from collaboration agreements |
| Jonathan Solomon Thank you, Marina, and good morning, everyone |
| Thank you again |
| In addition, Fast Track designation means that BX004 may also be eligible for rolling submission and priority review of Biologics License Application and/or a new drug application, which assures that questions and issues are resolved quicker, often leading to earlier drug approval and access by patients |
| We also added two highly accomplished pharmaceutical executives to our Board who collectively bring to BiomX considerable business and legal experience |
| Statement |
|---|
| With our patient screening efforts now complete, we estimate a four to six-week delay in our top line results for Part 2 of the study, now expected to be announced in November of this year |
| You remember all the difficulties we've had with recruiting Part 1 and the delay |
| It's driven, there are more patients that are going through, you know, kind of the pipeline, and some operational issues, nothing major |
| Net loss was $6.4 million for the second quarter of 2023 and compared to $7.5 million for the same period in 2022 |
| I want to focus back a bit on the delay of data with additional patients from here in Q3 in November |
| There is, as you've noted, a slight delay |
| A decrease in both salaries and stock-based compensation expenses, which resulted from a reduction in workforce as part of a corporate restructuring in 2022, and as well as deprioritizing preclinical and clinical activities related to our atopic dermatitis product candidate, BX005 |
| The decrease was primarily attributed to several factors |
Please consider a small donation if you think this website provides you with relevant information